炎症驱动的脱氨酶失调导致人类白血病前干细胞的进化。

Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution.

机构信息

Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA.

Center for Computational Biology & Bioinformatics (CCBB), Department of Medicine, University of California, San Diego, La Jolla, CA 92093-0681, USA.

出版信息

Cell Rep. 2021 Jan 26;34(4):108670. doi: 10.1016/j.celrep.2020.108670.

Abstract

Inflammation-dependent base deaminases promote therapeutic resistance in many malignancies. However, their roles in human pre-leukemia stem cell (pre-LSC) evolution to acute myeloid leukemia stem cells (LSCs) had not been elucidated. Comparative whole-genome and whole-transcriptome sequencing analyses of FACS-purified pre-LSCs from myeloproliferative neoplasm (MPN) patients reveal APOBEC3C upregulation, an increased C-to-T mutational burden, and hematopoietic stem and progenitor cell (HSPC) proliferation during progression, which can be recapitulated by lentiviral APOBEC3C overexpression. In pre-LSCs, inflammatory splice isoform overexpression coincides with APOBEC3C upregulation and ADAR1p150-induced A-to-I RNA hyper-editing. Pre-LSC evolution to LSCs is marked by STAT3 editing, STAT3β isoform switching, elevated phospho-STAT3, and increased ADAR1p150 expression, which can be prevented by JAK2/STAT3 inhibition with ruxolitinib or fedratinib or lentiviral ADAR1 shRNA knockdown. Conversely, lentiviral ADAR1p150 expression enhances pre-LSC replating and STAT3 splice isoform switching. Thus, pre-LSC evolution to LSCs is fueled by primate-specific APOBEC3C-induced pre-LSC proliferation and ADAR1-mediated splicing deregulation.

摘要

炎症依赖性碱基脱氨酶在许多恶性肿瘤中促进治疗耐药性。然而,它们在人类前白血病干细胞(pre-LSC)向急性髓系白血病干细胞(LSC)的进化中的作用尚未阐明。对来自骨髓增殖性肿瘤(MPN)患者的 FACS 纯化的 pre-LSC 的全基因组和全转录组测序分析显示,APOBEC3C 上调,C 到 T 的突变负担增加,以及进展过程中的造血干细胞和祖细胞(HSPC)增殖,这可以通过慢病毒 APOBEC3C 过表达来再现。在 pre-LSCs 中,炎症剪接异构体的过表达与 APOBEC3C 的上调和 ADAR1p150 诱导的 A 到 I RNA 超编辑同时发生。pre-LSC 向 LSC 的进化以 STAT3 编辑、STAT3β 异构体转换、磷酸化 STAT3 升高和 ADAR1p150 表达增加为标志,这可以通过 JAK2/STAT3 抑制剂鲁索替尼或 fedratinib 或慢病毒 ADAR1 shRNA 敲低来预防。相反,慢病毒 ADAR1p150 的表达增强了 pre-LSC 的再铺板和 STAT3 剪接异构体的转换。因此,pre-LSC 向 LSC 的进化是由灵长类动物特异性 APOBEC3C 诱导的 pre-LSC 增殖和 ADAR1 介导的剪接失调所驱动的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索